New combo therapy aims to zap liver cancer and keep it from coming back
NCT ID NCT03753659
Summary
This study tested whether adding an immunotherapy drug (pembrolizumab) to a standard tumor-destroying procedure (ablation) could better control early-stage liver cancer. It involved 30 patients eligible for ablation, aiming to see if the combination could shrink tumors before the procedure and help prevent the cancer from returning afterward. The goal was to improve outcomes for patients by using the body's immune system alongside the local treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hannover Medical School
Hanover, Lower Saxony, 30625, Germany
Conditions
Explore the condition pages connected to this study.